Ikänik Farms finalizes an initial pesticide & microbiological trial
Date: 2019-12-17   Author: Pankaj Singh  Category: #news

Ikänik Farms finalizes an initial pesticide & microbiological trial

In recent years, regulatory bodies have started to recognize the medicinal values of hemp. Numerous countries have legalized hemp production and commercialization for clinical applications. With growing demand, manufacturers are heavily investing in R&D to test novel cannabis-based products that are aimed at medical or agricultural use.

One such effort was recently taken by Ikänik Farms, Inc. which announced that its wholly-owned subsidiary, Ikänik Farms International, Inc. has successfully concluded its initial microbiological and pesticide testing of flower samples planted in Casa Flores, the firm's cannabis camp situated in Colombia.

According to reliable sources, the testing was led by Ikänik’s medical division Pideka SAS and was conducted by the University Jorge Tadeo Lozano. The findings revealed that Pideka’s sample flowers showed no traces of pesticides.

Reportedly, the tests reveals that the flowers, which were grown at Casa Flores, fulfilled every pharmaceutical-grade cannabis standard laid by the Council of Europe. Apparently, cannabis materials that go beyond the standardized heavy metals and pesticide parameters are categorized as non-pharmaceutical grade and are then barred from pharmaceutical exportation in the EU.

A separate microbiological test was also performed to authenticate that the substance was homogenous and had no systemic preclusions laid out by the European Pharmacopoeia, Europe's scientific and legal benchmark for pharmacopoeia standards.

Speaking on the move, Borja Sanz de Madrid, President, Ikänik International, said that the company is delighted to share the positive results from its microbiological and pesticide testing. This ends the initial phase of mandatory tests to develop a pharmaceutical-grade cannabis item.

Prior to this news, Ikänik International had made headlines when its inked a two-year partnership R&D agreement with Corporation for Biological Research (CIB) to create cannabis-based items for treating human diseases.

Sources close to the partnership reveal that the primary endpoint of this venture would be geared towards developing and researching cannabis-based products that prevent or slow the growth of colon cancer cells using therapy of cannabinoids via nanotechnology. Additionally, Ikänik Farms was assigned the task to produce cannabis plant material for CIB.
 

Source Credit: https://www.prnewswire.com/news-releases/ikanik-farms-completes-initial-pesticide-and-microbiological-testing-of-sample-flower-with-leading-colombian-laboratory-300975499.html



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Medical imaging firm Nanox raises $26M in a round led by Foxconn
Author: Saipriya Iyer

Nanox Imaging, an Israeli medical imaging startup, reportedly announced that it raised $26 million in an investment round, which was led by its strategic investor Foxconn. The total valuation of the company has reached...


Fitbit adds blood oxygen level monitoring feature in some devices
Author: Saipriya Iyer

Fitbit- a California based fitness wearables company has reportedly rolled out SpO2 sensors in its devices, enabling users to track their blood oxygen levels. In terms of percentage, between 95% to 100% of blood oxygen...


Modern Health closes $31 Mn funding led by John Doerr & Founders Fund
Author: Pankaj Singh

Modern Health, a startup company based in San Francisco, offering a comprehensive mental health platform for corporate employees, has recently closed a $31 Mn Series B funding round. It was led by Founders Fund and Joh...